H. Lundbeck A/S said its drug Vyepti was associated with greater improvement for some migraine sufferers in a clinical trial when compared with a placebo.
Vyepti was associated with larger declines in headache frequency and days of acute headache medication use in people diagnosed with both chronic migraine and medication overuse headache, the company said in a
The European Commission granted marketing authorization for Vyepti for the prophylactic treatment of migraine in adults who have at least four migraine days per month, the Danish pharmaceutical company said Jan. 24.
To contact the reporter on this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.